The Use of Chloroquine and Hydroxychloroquine for Non-infectious Conditions Other Than Rheumatoid Arthritis or Lupus: a Critical Review

Overview

Journal Lupus

Publisher Sage Publications

Specialty Rheumatology

Date 1996 Jun 1

PMID 8803913

Citations 12

Authors

D J Wallace

Affiliations

Soon will be listed here.

Abstract

Chloroquine and hydrocychloroquine have been evaluated in 30 noninfectious disorders and conditions other than rheumatoid arthritis or lupus erythematosus; 12 of these have been subjected to well-designed controlled trials. It is concluded that chloroquines are safe and effective first line therapies for selected patients with porphyria cutanea tarda, cutaneous sarcoidosis, cutaneous manifestations of dermatomyositis, hyperlipidemias and thromboembolic prophylaxis for patients with antiphospholipid antibodies. Published experience with these and other diseases or syndromes are critically reviewed.

Citing Articles

Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.

Rezaee H, Pourkarim F, Pourtaghi-Anvarian S, Entezari-Maleki T, Asvadi-Kermani T, Nouri-Vaskeh M Pharmacol Res Perspect. 2021; 9(1):e00705.

PMID: 33421347 PMC: 7796804. DOI: 10.1002/prp2.705.

COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.

Derwand R, Scholz M, Zelenko V Int J Antimicrob Agents. 2020; 56(6):106214.

PMID: 33122096 PMC: 7587171. DOI: 10.1016/j.ijantimicag.2020.106214.

The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.

Shah M, Sachdeva M, Dodiuk-Gad R Dermatol Ther. 2020; 33(4):e13524.

PMID: 32383251 PMC: 7267550. DOI: 10.1111/dth.13524.

Chloroquine and hydroxychloroquine in the context of COVID-19.

Shukla A, Archibald L, Wagle Shukla A, Mehta H, Cherabuddi K Drugs Context. 2020; 9.

PMID: 32373183 PMC: 7192209. DOI: 10.7573/dic.2020-4-5.

Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.

Esteve-Valverde E, Tapiz-Reula A, Ruiz D, Alijotas-Reig J Rheumatol Int. 2019; 40(5):777-783.

PMID: 31865445 DOI: 10.1007/s00296-019-04500-8.